Peptide Purity Testing: Identity, Content and Evidence Limits

PYXAX editorial reference

“99% purity” answers only a defined analytical question. It does not, by itself, tell you whether the expected compound is present, how much is in the sample, or whether a final container meets microbiological requirements. Start by naming the attribute you need to evaluate; then find the measurement that addresses it.

Identity ≠ chromatographic purity ≠ content ≠ sterility. These attributes can be investigated together, but one cannot stand in for the others. ICH’s analytical-validation framework distinguishes identification, impurity measurement and assay because each has a different intended purpose.¹

What each test actually tells you

The testing evidence matrix separates the analytical question each method addresses from the conclusions that require additional evidence.

The diagram is a general analytical-concepts matrix. It is not a list of tests performed on every PYXAX product. PYXAX’s exact-lot evidence policy is stated separately below.

The matrix deliberately says “typical evidence,” not “proof.” Method selectivity, recovery, detection limits, sampling and acceptance criteria determine how far a result can be used.¹²

HPLC and LC-MS answer different analytical questions

The method names are not conclusions. Read the sample, procedure, units, result and limitations reported by the source.¹²³

Which analytical evidence fits the question?

Start with the analytical question rather than a preferred instrument. The PYXAX analytical-question decision framework routes a documentation review toward relevant evidence while keeping the method’s limitations attached.

This framework interprets documentation; it is not an experimental procedure or a universal test panel. Continue to the HPLC guide or LC-MS guide only after identifying the question the report is meant to answer.

Identity: consistency with the expected material

Mass spectrometry measures ions by mass-to-charge ratio. LC-MS adds chromatographic separation before mass analysis. The expected mass calculation must match the molecular form and the mass convention used in the report. A chemically modified peptide, an adduct and a different charge state can change how a spectrum should be read.³

An expected-versus-observed intact mass comparison can support identity, but it is not a complete sequence readout. More detailed questions may require fragmentation, mapping, reference comparisons or other complementary evidence. The LC-MS guide explains what to request when a report shows several peaks for one peptide.

Purity: inspect the method and the denominator

For an uncorrected area-normalization result, the basic idea is:

Main peak area ÷ total included peak area × 100.

This is a description of a calculation, not a universal specification. Some methods apply relative response factors or different inclusion rules. A minor peak that is unresolved, below a reporting threshold or weakly detected may not contribute in the way the reader expects. Waters’ documentation distinguishes measured area from response-corrected area.⁴

Two laboratories can obtain different percentages without either number being invented. Compare their columns, mobile phases, gradients, detectors, wavelengths, integration settings and preparation. A percentage becomes interpretable when its method and peak table are available. See the annotated HPLC example.

Content: how much of what, on which basis?

A quantitative assay should identify the measurand, units, sample preparation and calibration basis. A result might describe an amount in a submitted sample, a concentration, or content relative to a label claim. Those are not interchangeable descriptions.¹

Gross powder mass can include counterions and moisture. Net peptide content and chromatographic purity describe different aspects of that material.⁵ A result of 99% HPLC area purity therefore cannot be converted directly into a verified amount per vial by multiplying it by the label.

Also distinguish the word potency as used by a particular report. A supplier may use it for amount against a label claim; a biological assay may use it for a functional response. Read the definition and method before equating the two. A content result does not independently measure receptor activity.

Microbiological and other attributes need their own evidence

Sterility testing addresses viable microorganisms under defined test conditions; endotoxin testing addresses a different attribute. Endotoxin assessment requires attention to sample interference and method suitability. Do not transfer a purity percentage into a microbiological conclusion.²

Likewise, elemental impurities and residual solvents require methods capable of measuring the specified substances. Stability requires evidence over time under defined conditions. Container integrity concerns the container/closure system. These are separate questions even when one laboratory can perform several of the analyses.

For a research project, ask the responsible laboratory which attributes are relevant to its experiment and which evidence is needed. This guide does not prescribe a universal “full panel,” a cell-assay acceptance limit or a certificate format that every supplier must use.

Read the evidence in a useful order

1. Match the sample. Establish the compound, form and lot before comparing results.
2. Name the question. Identity, relative impurities, amount and contamination are different questions.
3. Read the method. Check that the reported procedure addresses that question.
4. Read the units and result basis. Area percent, mass, concentration and a pass/fail assessment need different interpretation.
5. Read the boundaries. Look for reporting limits, sampling context and what was not evaluated.
6. Preserve the record. Keep the complete document, revision and related clarification with the material’s laboratory record.

This is an editorial review workflow, not a validation procedure. The COA interpretation guide provides the field-by-field matching checklist.

When apparently strong results still leave a gap

High area purity but no amount assay: relative chromatographic composition may be reported while the quantity in the submitted container remains unmeasured.

Mass consistent with the target but several chromatographic peaks: identity evidence for a detected component does not establish that all other material is the same compound.

A complete report for a different lot: the analytical detail does not repair the missing connection to the material at hand.

A recent test date but no stability study: the initial measurement does not establish how long the material remains within a specification. See storage and handling for documentation questions.

These are examples of missing evidence, not accusations about a supplier.

PYXAX’s current testing scope

PYXAX records testing at the lot level. The COA Library shows whether documentation for a listed record is published or pending; only the exact published certificate establishes the issuing laboratory, methods and results for that lot. When a record reports HPLC purity, LC-MS identity or content against a label claim, each result must be read on its own terms. Endotoxin, heavy-metals and final-vial sterility must not be inferred unless suitable evidence is reported for that exact material.

Read actual records in the COA Library. For a compound-specific example of why identity matters, the Retatrutide/Tirzepatide research comparison separates receptor classification from the evidence for a supplied lot.

References

All PYXAX compounds are supplied strictly for in-vitro and preclinical laboratory research use only. Not for human consumption. Not for veterinary use. Not for diagnostic procedures. These statements have not been evaluated by the FDA. Researchers are responsible for compliance with all applicable laws and regulations governing the use of research compounds in their jurisdiction.